Changes for page AstraZeneca
Last modified by Wilton Risenhoover on 2022/07/06 01:12
Change comment:
There is no comment for this version
Summary
-
Page properties (2 modified, 0 added, 0 removed)
-
Objects (0 modified, 0 added, 1 removed)
Details
- Page properties
-
- Tags
-
... ... @@ -1,1 +1,0 @@ 1 -US:AZN|GB:AZN - Content
-
... ... @@ -6,11 +6,13 @@ 6 6 7 7 * AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. 8 8 * The company focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. 9 -* The company also has an active R&D presence in 40 other countries spanning the globe with 10,000 - employees work exclusively in R&D.9 +* The company also has an active R&D presence in 40 other countries spanning the globe with 0,000 - employees work exclusively in R&D. 10 10 * Commercial teams of around 43,400 employees are active in more than 100 countries 11 11 12 + 12 12 [[image:AZN0.png||height="175" width="721"]] 13 13 15 + 14 14 = Company Overview = 15 15 16 16 AstraZeneca (LSE:AZN, NASDAQ:AZN) is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide.{{footnote}}https://www.astrazeneca.com/our-company.html{{/footnote}} ... ... @@ -30,6 +30,7 @@ 30 30 * 40 - active R&D presence in other countries spanning the globe 31 31 * 10,000 - employees work exclusively in R&D 32 32 35 + 33 33 The company's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. 34 34 35 35 * 175projects in its pipeline ... ... @@ -36,6 +36,7 @@ 36 36 * 17new molecular entities in its late-stage pipeline 37 37 * 1new molecular entity approval 38 38 42 + 39 39 [[image:AZN4.png||alt="AZN2.png"]] 40 40 41 41 ... ... @@ -82,6 +82,7 @@ 82 82 * Building expertise and leadership in the most prevalent and highest mortality rate tumour types 83 83 * Delivering across its global footprint 84 84 89 + 85 85 **key disease areas** 86 86 87 87 The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients. ... ... @@ -236,18 +236,17 @@ 236 236 237 237 **Emerging Markets** 238 238 239 -Emerging Markets, as defined in Market definitions on page 280, comprise various countries with dynamic, growing economies. As outlined in Healthcare in a changing world from these countries represent a major growth opportunity for the pharmaceutical industry due to high unmet medical need and sound economic fundamentals. Emerging Markets are not immune, however, to economic downturn. Market volatility is higher than in Established Markets, and various political and economic challenges exist. These include regulatory and government interventions. In selected markets, governments are encouraging local manufacturing and investment by offering more favourable market access conditions and pricing is increasingly controlled by payers through price referencing regulations in addition to cost effectiveness and cost minimisation approaches. 244 +Emerging Markets, as defined in Market definitions on page 280, comprise various countries with dynamic, growing economies. As outlined in Healthcare in a changing world from page 12, these countries represent a major growth opportunity for the pharmaceutical industry due to high unmet medical need and sound economic fundamentals. Emerging Markets are not immune, however, to economic downturn. Market volatility is higher than in Established Markets, and various political and economic challenges exist. These include regulatory and government interventions. In selected markets, governments are encouraging local manufacturing and investment by offering more favourable market access conditions and pricing is increasingly controlled by payers through price referencing regulations in addition to cost effectiveness and cost minimisation approaches. 240 240 241 241 242 242 Growth drivers for Emerging Markets include new medicines across its Oncology, CVRM and Respiratory & Immunology portfolios. To educate physicians about its broad portfolio, AstraZeneca is selectively investing in sales capabilities where opportunities from unmet medical need exist. AstraZeneca is also expanding its reach through multi-channel marketing and external partnerships. 243 243 244 244 245 -With revenues of $8,711 million (2019: $8,171 million), AstraZeneca was the fourth largest multinational pharmaceutical company, as measured by prescription sales, and the second fastest-growing top 10 multinational pharmaceutical company in Emerging Markets in 2020. Despite the impact of COVID-19 across all geographies the company saw growth across all major areas including Latin America at 12% (18% at CER), Russia & Eurasia at 26% (39% at CER), Middle East & Africa down 4% (up 1% at CER) and Asia Area at 5% (7% at CER).250 +With revenues of $8,711 million (2019: $8,171 million), AstraZeneca was the fourth largest multinational pharmaceutical company, as measured by prescription sales, and the second fastest-growing top 10 multinational pharmaceutical company in Emerging Markets in 2020. Despite the impact of COVID-19 across all geographies the company saw growth across all major areas including Latin America at 0% (18% at CER), Russia & Eurasia at 26% (39% at CER), Middle East & Africa down 4% (up 1% at CER) and Asia Area at 5% (7% at CER). 246 246 247 247 248 248 [[image:AZN2.png]] 249 249 250 -{{putFootnotes/}} 251 251 252 252 = Financial Highlights = 253 253 ... ... @@ -261,6 +261,7 @@ 261 261 * Alexion integration progressing well, creating new opportunities in rare diseases 262 262 * Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in its COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery 263 263 268 + 264 264 **Pascal Soriot, Chief Executive Officer, commented:** 265 265 266 266 AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including its long acting antibody combination showing promise in both prevention and treatment of COVID-19. The addition of Alexion furthers its commitment to bring transformative therapies to patients around the world, and I am proud of its colleagues’ ongoing dedication and focus. ... ... @@ -279,6 +279,7 @@ 279 279 * In the US, Total Revenue increased by 29% to $8,305m and in Europe by 40% (31% at CER) to $5,178m, including pandemic COVID-19 vaccine revenue of $736m 280 280 * Growth in Core EPS13 to $5.05 to $5.40, in line with prior guidance. 281 281 287 + 282 282 Oncology Total Revenue of $9,744m in the year to date; an increase of 19% (16% at CER). Oncology represented 38% of overall Total Revenue (YTD 2020: 43%). 283 283 284 284
- XWiki.XWikiComments[0]
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.AsifF - Comment
-
... ... @@ -1,2 +1,0 @@ 1 -Recent investor presentation 2 -https://www.astrazeneca.com/content/dam/az/PDF/2021/q3/Year-to-date_and_Q3_2021_results_presentation.pdf - Date
-
... ... @@ -1,1 +1,0 @@ 1 -2022-01-12 13:31:12.795